Acrivon Therapeutics (NASDAQ:ACRV) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.09, Zacks reports.

Acrivon Therapeutics Stock Down 9.4 %

Shares of Acrivon Therapeutics stock traded down $0.21 on Monday, hitting $2.03. The stock had a trading volume of 273,965 shares, compared to its average volume of 262,182. The stock has a market cap of $63.21 million, a price-to-earnings ratio of -0.75 and a beta of 0.85. Acrivon Therapeutics has a twelve month low of $2.02 and a twelve month high of $11.90. The business's 50 day moving average is $5.27 and its two-hundred day moving average is $6.45.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Acrivon Therapeutics in a research report on Wednesday, March 26th. HC Wainwright dropped their price objective on Acrivon Therapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Wednesday, March 26th. Finally, KeyCorp assumed coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an "overweight" rating for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics presently has a consensus rating of "Buy" and an average price target of $23.17.

Remove Ads

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.